Tag: paroxetine and suicide

An interview with Wendy Dolin who talks about the work of MISSD, the Medication-Induced Suicide Prevention and Education Foundation in Memory of Stewart Dolin, a non-profit founded to raise awareness of the tragic consequences of drug-induced akathisia.

From The American Lawyer: "A federal appeals court has thrown out a $3 million verdict awarded last year to the widow of a former Reed...

The jury was out for days. And when they came back it became clear they were wrestling with the issue of who to blame. This was like playing Go, where it can look like the black counters on the board have white encircled until white puts down one more piece and all of a sudden it wins.

Finally, faced with the twenty known and two possible suicides on Paxil during clinical trials, Dr. Kraus reluctantly conceded that 80% of the victims were over thirty. Whatever they had told the FDA, the risks of Paxil could not be confined to adolescents — and GSK knew it.

In July of 2010, Stewart Dolin, a partner at the mega law firm Reed Smith, jumped in front of a subway train in Chicago, apparently suffering from akathisia caused by paroxetine. His widow sued, and the jury found GSK negligent in not informing doctors of the suicide risk

Most doctors still affect surprise at the idea SSRIs might come with withdrawal problems. Regulators knew very clearly since 2002 about the problems, but have decided to leave any communication of these issues in company hands.

All the fuss about Study 329 centers on its 8-week acute phase. But this study had a 24-week Continuation Phase that has never been published. Until Now.

When we set out to restore GSK’s misreported Study 329 of paroxetine for adolescent depression under the RIAT initiative, we had no idea of the magnitude of the task we were undertaking. After almost a year, we were relieved to finally complete a draft and submit it to the BMJ, who had earlier indicated an interest in publishing our restoration. But that was the beginning of another year of peer review that we believed went beyond enhancing our paper and became rather an interrogation of our honesty and integrity. Frankly, we were offended that our work was subject to such checks when papers submitted by pharmaceutical companies with fraud convictions are not.

The meaning of veterans’ reactions to war is quite simple; they are trying to find a way to integrate the incredible horrors they’ve witnessed and to find a way to come back into a society that cannot possibly fully understand them. Drugging them into a stupor is not the answer. Congressman David Jolly (FL-13) has recently introduced the Veteran Suicide Prevention Act (H.R. 4640). The bill calls for the VA to study veteran suicides over the past five years and to determine what extent psychiatric drugs are implicated in those suicides. I encourage everyone to support Mr. Jolly’s bill by writing or calling your congressional representatives and encouraging them to cosponsor the bill.

Access to data is more important than access to information about conflicts of interest. It is only when there is access to the data that we can see if interests are conflicting and take that into account. Problems don’t get solved unless someone is motivated for some reason. We need the bias that pharmaceutical companies bring to bear in their defense of a product, along with the bias of those who might have been injured by a treatment. Both of these biases can distort the picture but it’s when people with differing points of view agree on what is right in front of their noses that we can begin to have some confidence about what we have.